Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients

Overview

case control study to compare level of interleukin 38 in patients with psoriasis and patients with metabolic syndrome with healthy control subjects

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: May 2022

Detailed Description

this case control study will measure plasma level of interleukin 38 in 4 groups of 24 subject, group one will have psoriatic patients, group 2 will have psoriatic patients with metabolic syndrome, group three will have patients with metabolic syndrome only, and group 4 will have healthy control subjects.

Interventions

  • Diagnostic Test: measure plasma level of interleukin 38 by ELISA kit
    • draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test

Arms, Groups and Cohorts

  • Group 1 (Psoriasis only)
    • contains 24 psoriatic patients, Psoriasis Area Severity Index will be measured, also waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile and finally: plasma level of interleukin 38
  • Group 2 (Psoriasis and metabolic syndrome)
    • contains 24 psoriatic patients with metabolic syndrome. Psoriasis Area Severity Index will be measured metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
  • Group 3 (Metabolic syndrome only)
    • contains 24 patients with metabolic syndrome only. full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
  • Group 4 (Healthy Controls)
    • contains 24 healthy control subjects full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is excluded after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38

Clinical Trial Outcome Measures

Primary Measures

  • can we predict occurrence of metabolic syndrome in psoriatic patients?
    • Time Frame: through study completion an average of 18 months
    • level of interleukin 38 will be measured and compared in all groups to asses the relationship between this interleukin and metabolic syndrome in psoriatic patients

Participating in This Clinical Trial

Inclusion Criteria

  • specific to each group Exclusion Criteria:

  • Patient refusal. Age <18 years Pregnancy Lactation smoking Infections. Patients with other inflammatory skin disorders use of antioxidant and anti-inflammatory drugs patients on treatment for psoriasis

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Sohag University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Yomna Abdo Abdellatif, resident doctor in dermatology venereology and andrology department in sohag university hospital – Sohag University
  • Overall Official(s)
    • yomna a abdellatif, MBBCH, Principal Investigator,
  • Overall Contact(s)
    • Yomna A Abdellatif, MBBCH, 01119200320, yomna.a.abdellatif@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.